Search hospitals > Connecticut > New Haven
Yale University
Claim this profileNew Haven, Connecticut 06510
Global Leader in Skin Cancer
Global Leader in Cancer
Conducts research for Uterine Tumors
Conducts research for Relapse
Conducts research for Breast Cancer
1112 reported clinical trials
192 medical researchers
Summary
Yale University is a medical facility located in New Haven, Connecticut. This center is recognized for care of Skin Cancer, Cancer, Uterine Tumors, Relapse, Breast Cancer and other specialties. Yale University is involved with conducting 1,112 clinical trials across 1,690 conditions. There are 192 research doctors associated with this hospital, such as Nina S. Kadan-Lottick, Farzana Pashankar, Patricia M Lorusso, and Alessandro Santin.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Nina S. Kadan-LottickMedStar Georgetown University Hospital7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
37 reported clinical trials
83 drugs studied
Farzana PashankarYale University7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
33 reported clinical trials
78 drugs studied
Patricia M LorussoYale Cancer Center6 years of reported clinical research
Expert in Solid Tumors
Expert in Uterine Tumors
27 reported clinical trials
43 drugs studied
Alessandro SantinSmilow Cancer Hospital at Yale New Haven5 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
17 reported clinical trials
25 drugs studied
Clinical Trials running at Yale University
Breast Cancer
Lung Cancer
Skin Cancer
Multiple Myeloma
Small Cell Lung Cancer
Testicular cancer
Breast cancer
Pancreatic Cancer
Plasma Cell Neoplasm
Non-Small Cell Lung Cancer
Sacituzumab Tirumotecan + Pembrolizumab
for Breast Cancer
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Recruiting2 awards Phase 33 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Yale University?
Where is Yale University located?
Who should I call to ask about financial aid or insurance network?
What insurance does Yale University accept?
What awards or recognition has Yale University received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.